Raymond James Reiterates Outperform Rating on Cytokinetics (CYTK), PT $81

April 2, 2025 1:46 PM EDT Send to a Friend
Raymond James analyst Dane Leone reiterated an Outperform rating and $81.00 price target on Cytokinetics (NASDAQ: CYTK)The analyst comments "Wednesday ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login